TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, cilt.20, sa.2, ss.173-177, 2011 (ESCI)
INTRODUCTION: Treatment of membranoproliferative glomerulonephritis (MPGN) is often unrewarding with approximately 60% of patients progressing to end-stage renal failure within 10 years. In our study, we compared the efficacy of CS alone versus low dose CS + another immunosuppressive agent retrospectively. MATERIAL and